All In Biotech

Drug Trial Radar · NCT04017338

Transplantation Using Hepatitis C Positive Donors, A Safety Trial

Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients: A Safety Trial

Last checked: Nov 20, 2026Latest source record: Jul 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 6, 2018

Primary completion

Dec 31, 2020

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Jordan FeldAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Health Network, Toronto
First posted
Jul 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The success of transplantation is significantly hindered by the lack of sufficient number of available donors. Many potential donor organs cannot be utilized in clinical transplantation because donors have chronic viral infections such as hepatitis C (HCV) infection. This study will test the possibility of safely transplanting organs from HCV-infected donors into HCV-uninfected recipients. Prior to transplantation, recipients will receive an initial dose of highly effective antiviral prophylaxis using approved direct-acting antivirals (DAAs) Glecaprevir/Pibrentasvir (G/P) and they will also receive ezetimibe, a cholesterol-lowering medication that also blocks entry of HCV into liver cells. They will then receive daily dosing of the same medications for 7 days after transplant. The aim of the study is to show that transplantation of organs from HCV+ donors is safe in the era of DAAs. The investigators hypothesize that rates of HCV transmission to recipients will be prevented by the use of DAA prophylaxis and any HCV transmission that does occur will be readily treatable and curable. If successful, the knowledge from this study can have a large impact to patients with end stage organ diseases by providing a large novel source of donors for organ transplantations.

Conditions

  • Lung Transplant Infection
  • Heart Transplant Infection
  • Kidney Transplant Infection
  • Kidney Pancreas Infection
  • Hepatitis C

Interventions

  • Glecaprevir 300 MG / Pibrentasvir 120 MG Oral TabletDrug

    A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.

  • Ezetimibe 10Mg Oral TabletDrug

    A cholesterol-lowering medication that also blocks entry of HCV into liver cells.

  • Ex Vivo Lung PerfusionDevice

    A technology that allows for the assessment and treatment of lungs prior to transplant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-transplant Survival [Safety]Time frame: 6 months
  2. Incidence of HCV transmission [Safety]Time frame: 6 months
  3. Incidence of treatment-emergent adverse events [Safety and Tolerability]Time frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Health Network Toronto General Hospital

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.